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OBJECTIVE: This retrospective study examined both the
use of abciximab treatment and its impact on hospital
length of stay among angioplasty patients enrolled in
managed care organizations.
METHODS: Retrospective billing data was obtained for
a sample of 1847 angioplasty patients who were enrolled
in US managed care organizations. Multivariate analysis
was used to control for a wide range of factors (patient
demographics, comorbidities, admission and discharge
information, and hospital characteristics such as region
of the country, size, number of angioplasties performed
per year) that may influence a patient’s likelihood of re-
ceiving abciximab or impact their length of stay in the
hospital. Estimation was conducted via a two-stage sam-
ple selection model.
RESULTS: Patients in poorer health were more likely to
receive abciximab. After controlling for high-risk indica-
tions and selection bias, results indicate that in contrast
with studies involving other payers, women and minori-
ties enrolled in these managed care organizations had the
same access to abciximab as other members. Further-
more, results indicate that angioplasty patients who were
given abciximab had a significantly shorter length of stay
(0.59 fewer days  0.24 days) than those patients who
did not receive abciximab.
CONCLUSIONS: These findings indicate that there are
potential economic benefits for hospitals administering ab-
ciximab. Given that hospital length of stay has been found
to be one of the most important determinants of total
healthcare costs, the reduced length of stay found in this
study implies cost off-sets for patients receiving abciximab.
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OBJECTIVE: To determine the outcomes associated with
a falls risk-reduction program.
METHODS: Medical and pharmacy claims data for
33,208 Medicare supplemental insurance plan patients
 75 years of age were evaluated. Each patient’s individ-
ual diagnosis- and drug-related risk factors were analyzed,
and providers for those patients at greatest risk received a
patient-specific educational intervention. Intermediate out-
comes (the mean number of high-risk drugs and the total
number of drugs prescribed) were evaluated before and for
9 months post-intervention in a study population of 1818
patients.
RESULTS: Pre-intervention there was a trend of escalat-
ing drug use in this population. Post-intervention, there
was a reduction (p  0.01) in the mean number of drugs
(	0.61) and high-risk drugs (	0.49). A retrospective
comparison population of 2211 patients showed an in-
crease (p  0.01) in the mean number of drugs (2.2)
and high-risk drugs (0.77) prescribed over a similar
time interval. Regression to the mean and selective mor-
tality do not appear to account for the results observed.
Examining the medical and economic benefits resulting
from this reduction in drug use has proven to be prob-
lematic. Falls are poorly documented in claims data.
Consequences of falls (e.g. hip fracture) can be identified
through claims review, but the incidence of these conse-
quences is relatively low, and differentiation between ini-
tial and follow up care is difficult. Several comparison
populations were evaluated for use in outcomes assess-
ment, but each has significant limitations. Also, medical
and economic benefits from a risk-reduction program
would be expected to accrue over an extended period of
time.
CONCLUSION: The intervention impacted the interme-
diate outcomes, but barriers prohibited analysis of poten-
tial medical and economic benefits.
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OBJECTIVE: Although economic evaluations are increas-
ingly conducted on a multinational basis, the issue of how
to analyze and interpret multinational economic data has
received little attention. This research illustrates the use of
cluster analysis to investigate patterns in resource utiliza-
tion between different countries or centers, and examines
the use of multilevel modeling to explicitly detect a hierar-
chical structure to the data if one is present and to explore
the relationship between site and outcome.
METHODS: The cluster analysis and multilevel model-
ing using SPSS for Windows and MLn, were based upon
resource utilization data captured in a multinational
phase III randomized controlled trial of two alternative
drug treatments for rheumatoid arthritis. In this trial,
data (e.g., inpatient episodes, outpatient visits, therapeu-
tic procedures, diagnostic procedures, GP visits, physio-
therapy sessions) were collected for 374 patients over a
108-week period, enrolled at 56 centers in nine European
countries. Clustering was investigated employing various
linkage and distance measures, and parameters were esti-
mated for the multilevel model specified with countries as
level 3 units, centers as level 2 units, and patients as level
1 units.
RESULTS: A variety of clustering solutions were gener-
ated according to the resource category examined and
visually presented in dendrogramatic form and icicle
plots. Across all categories, the countries resolved into
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four clusters (cluster 1  UK, Denmark, Norway, Nether-
lands; cluster 2  Germany, Finland; cluster 3  Belgium;
cluster 4  France). In the multilevel model, variances were
observed operating at the different levels which could be ex-
plained in terms of the general characteristics of the sites.
CONCLUSIONS: The results of this analysis suggest that
cluster analysis and multilevel modeling techniques can
be valuable tools in the exploration of multinational eco-
nomic data, although they require considerable care in
practice. The presence of clustering may have important
implications for costing and the pooling of multinational
economic evaluation data.
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OBJECTIVES: The purpose of this study was to evaluate
the impact of price change on the willingness to pay
(WTP) of patients with urinary incontinence.
METHODS: A sample of 41 women with urinary incon-
tinence (UI) from Seattle and Philadelphia were inter-
viewed. The questionnaire contained a WTP question
with 11 bids ranging from $1 to $200. Two versions of
the questionnaire were administered, one for “improve-
ment” and one for “cure.” Respondents recorded whether
they would accept or reject each bid (“price”) at the
stated dollar value. The analysis was conducted using the
modified price elasticity concept defined by the percent
change in the number of people who were willing to pay
divided by the percent change in price.
RESULTS: Elasticity comparison between improvement
and cure showed that, in general, people’s WTP was
more “elastic” for improvement than it was for cure. In
the lower price range (from $10 to $50), the WTP for both
improvement and cure were inelastic (elasticity less than
one). For the higher price range ($50 to $200), only WTP
for improvement showed elasticity greater than one.
CONCLUSIONS: Regardless the price range, people are
more sensitive to the price change for a scenario promising
“improvement” than they are for “cure.” Therefore,
changes in price affect patients’ WTP for improvement
more than it will for cure. For a price range up to $50,
people will react similarly to price changes for both “im-
provement” and “cure.” People will react differently,
however (more elastic to improvement) at a price range
greater than $50. Therefore, the issue of the treatment out-
come (improvement versus cure) has a notable impact on
patient WTP when costs to them exceed $50.
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With the ongoing discussion about whether both costs
and outcomes should be discounted, alternate model con-
struction reflecting these options can be very informative.
Furthermore, the area of osteoporosis would dictate that
age adjusted fracture rates would be a particularly influ-
ential component to consider in model construction.
OBJECTIVE: This analysis reports the impact of step-
wise inclusion of the discounting costs and outcomes and
an age-adjustment on increment cost-effectiveness ratios.
METHODS: The two alternatives included hormone re-
placement therapy with calcium supplementation com-
pared with calcium supplementation alone in a cohort of
women age 50 to 90 years. The effectiveness measure
was fractures avoided.
RESULTS: The base model discounts only costs with no
age-adjustment for fracture rates (incremental CER:
$56,178.16, favoring hormone therapy). The model dis-
counting both costs and outcomes with no age-adjustment
for fracture rates, resulted in an incremental CER of
$37,817.38 per fracture avoided. Age-adjustment of frac-
ture rates resulted in incremental CER of $83,561.59 per
fracture avoided (discounted costs only) and $42,232.68
per fracture avoided (discounted costs and outcomes). All
models favored hormone replacement therapy and did
not result in any decision changes. At the end of 40 years,
Markov analysis demonstrated that age-adjustment of
fracture rates induced a shift to more desirable states. The
most dramatic shift was 14.87 and 5.15 more women out
of 1000 alive with no fracture in the hormone and calcium
arms, respectively.
CONCLUSION: The effect of discounting did not
change the decision outcome of the osteoporosis Markov
model. However, the magnitude of the change in Markov
state composition was dramatic as a result of the age ad-
justment to fracture rates.
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Tailoring the results from clinical trials and associated
pharmacoeconomic analyses to specific populations is
frequently requested by managed care companies. Mod-
els based on clinical trials and analyses often use pub-
lished results that typically present only study means (or
means and variances). However, underlying distributions
of results are not always normally or uniformly distrib-
uted, leading to potentially biased model predictions.
